You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

bevacizumab

( be-vuh-SIZ-uh-mab )
Funding:
New Drug Funding Program
  • Bevacizumab - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
  • Bevacizumab in combination with paclitaxel and carboplatin - Front-line Treatment Ovarian Fallopian Tube and Primary Peritoneal Cancer
  • Bevacizumab - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
  • Bevacizumab for Platinum-Resistant Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer
  • Bevacizumab - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
  • Bevacizumab - Metastatic (Stage IVB) Persistent or Recurrent Carcinoma of the Cervix
  • Bevacizumab (Biosimilar) - First Line - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
  • Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
  • Bevacizumab (Biosimilar) with Paclitaxel and Carboplatin - Front-line Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Other Name(s): Avastin®; Mvasi™
Appearance: Clear, colourless solution mixed into larger bags of fluids

You might also be interested in